SCHEMBL5440310

SCHEMBL5440310

CCN(CC)C(=O)c1cncc(-c2ccc(C(=O)OC)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 2/20 0.51
▸ CYP11B2 P19099 2/20 0.51
▸ HPGD P15428 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ ABL1 P00519 1/20 0.48
▸ BCR P11274 1/20 0.48
▸ XDH P47989 2/20 0.46
▸ SLC2A1 P11166 1/20 0.45
▸ MKNK1 Q9BUB5 2/20 0.45
▸ MKNK2 Q9HBH9 2/20 0.45
▸ S1PR1 P21453 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ ATM Q13315 1/20 0.43
▸ CYP2A6 P11509 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5424848 0.85 HPGD (0.67) CYP11B1CYP11B2HPGDLMNATSHR
SCHEMBL27986640 0.85 HPGD (0.56) HPGDLMNATSHRALDH1A1MAPT
SCHEMBL5422107 0.85 MKNK1 (0.58) CYP11B1CYP11B2HPGDLMNATSHR
SCHEMBL5437021 0.82 SCN10A (0.52) CYP11B1CYP11B2HPGDLMNATSHR
SCHEMBL5424646 0.82 HPGD (0.47) HPGDLMNATSHRALDH1A1MAPT
SCHEMBL5430912 0.81 LMNA (0.51) CYP11B1CYP11B2HPGDLMNATSHR
SCHEMBL7669610 0.80 ALDH1A1 (0.61) HPGDLMNAALDH1A1MAPTCYP1A2
SCHEMBL5430302 0.80 HPGD (0.49) CYP11B1CYP11B2HPGDLMNATSHR
SCHEMBL641553 0.79 CYP11B1 (0.60) CYP11B1CYP11B2ALDH1A1MAPTXDH
SCHEMBL5418318 0.76 CYP1A2 (0.47) HPGDLMNATSHRALDH1A1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 — — US claimed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 — — EP claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 — — US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 — — WO claimed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 — — WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 — — US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 — — US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 — — US disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 CYP11B1 497/4885CYP11B2 502/4885HPGD 158/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 CYP11B1 497/4885CYP11B2 502/4885HPGD 158/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 CYP11B1 205/4885CYP11B2 306/4885HPGD 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback